KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Acadia Pharmaceuticals (ACAD) over the last 5 years, with Sep 2025 value amounting to $170.7 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) rose 2.69% to $170.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.7 million, marking a year-over-year increase of 2.69%. This contributed to the annual value of $166.4 million for FY2024, which is 1.55% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $170.7 million, which was up 1.17% from $168.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $170.7 million during Q3 2025, with a 5-year trough of $160,421 in Q2 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $166.2 million in 2024 and averaged $166.2 million.
  • Data for Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY surged of 101,998.31% (in 2023) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $160,493 in 2021, then skyrocketed by 100,641.47% to $161.7 million in 2022, then increased by 1.32% to $163.8 million in 2023, then grew by 1.55% to $166.4 million in 2024, then climbed by 2.69% to $170.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $170.7 million for Q3 2025, versus $168.7 million for Q2 2025 and $167.7 million for Q1 2025.